BLTEBelite Bio, Inc American Depositary Shares

ADRCNasdaq (XNAS)·USD

Identity

Security key: 12653
Ticker: BLTE
Type: ADRC — American Depository Receipt Common
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2022-04-29
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: BLTE

Detail

Enriched 2026-08-14 20:47

Market cap: $7,172,826,183.54
Shares outstanding (class): 40,085,091
Shares outstanding (weighted): 40,085,091
SIC: —
Employees: 41
Location: —
Homepage: https://www.belitebio.com
Description: Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Market cap and share counts drift.

Funds holding this security

14 funds · 14 positions · $48.79M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$33.14M	0.30%	207,862 NS	FIGI
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$4.63M	0.29%	29,026 NS	FIGI
Morgan Stanley Discovery Portfolio Brighthouse Funds Trust I	—	$2.54M	0.23%	15,913 NS	FIGI
T. Rowe Price Health Sciences Portfolio T. ROWE PRICE EQUITY SERIES, INC.	—	$2.02M	0.31%	12,700 NS	FIGI
State Street(R) SPDR(R) Portfolio Emerging Mark… SPDR INDEX SHARES FUNDS	SPEM	$1.99M	0.01%	12,456 NS	FIGI
Discovery Portfolio MORGAN STANLEY INSTITUTIONAL FUND TRUST	—	$1.73M	0.23%	10,859 NS	FIGI
Health Sciences Trust John Hancock Variable Insurance Trust	—	$765.3K	0.34%	4,800 NS	FIGI
EQ/T.Rowe Price Health Sciences Portfolio EQ Advisors Trust	—	$526.2K	0.33%	3,300 NS	FIGI
State Street(R) SPDR(R) S&P(R) China ETF SPDR INDEX SHARES FUNDS	GXC	$508.9K	0.11%	3,192 NS	FIGI
Discovery Portfolio MORGAN STANLEY VARIABLE INSURANCE FUND INC.	—	$394.5K	0.23%	2,474 NS	FIGI
Global Endurance Portfolio MORGAN STANLEY INSTITUTIONAL FUND INC	—	$327.3K	2.11%	2,053 NS	FIGI
Parametric Tax-Managed Emerging Markets Fund Eaton Vance Series Trust II	—	$124.5K	0.02%	781 NS	FIGI
Alger Small Cap Growth Portfolio ALGER PORTFOLIOS	—	$78.0K	0.06%	489 NS	FIGI
T. Rowe Price Innovation Leaders ETF T. Rowe Price Exchange-Traded Funds, Inc.	TNXT	$18.7K	0.12%	117 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERBLTE
FIGI_COMPOSITEBBG016LJYT18
FIGI_SHARE_CLASSBBG016LJYTW4
CIK0001889109
ISINUS07782B1044
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Belite Bio is a clinical-stage biopharmaceutical company developing therapies for retinal diseases, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.